The post Covalent inhibitors of the PI3Kα RAS binding domain impair tumor growth driven by RAS and HER2 appeared first on Vividion Therapeutics.| Vividion Therapeutics
Chemoproteomics screening platform identified novel covalent inhibitors that specifically disrupt RAS-mediated activation of the catalytic subunit of PI| Vividion Therapeutics
We are bringing more disease-causing targets within the reach of small molecule therapeutics to transform care for patients with devastating diseases not| Vividion Therapeutics
Dr. Whiting brings extensive experience in medical oncology spanning patient care, early drug discovery, and late-stage global development activities His| Vividion Therapeutics
VVD-214 is the only clinical-stage covalent inhibitor of Werner helicase (WRN) in development worldwide WRN inhibition may provide therapeutic benefit in| Vividion Therapeutics
San Diego, CA, USA, Berlin, Germany April 3, 2025 – Vividion Therapeutics, Inc. (Vividion) today announced that the first patient has been dosed in a Phase I clinical trial evaluating VVD-159642, an investigational oral inhibitor designed to target RAS-driven cancers. Vividion is a clinical-stage biopharmaceutical company, and a wholly owned and independently operated subsidiary of Bayer […] The post Vividion Therapeutics Doses First Patient in Phase I Study of RAS-PI3Kα Inhibitor for T...| Vividion Therapeutics
San Diego, CA, USA January 22, 2025 – Vividion Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing novel discovery technologies to unlock high-value, traditionally undruggable targets and develop small molecule precision therapeutics for devastating cancers and immune disorders, today announced the promotion of Jean Bemis to Chief Operating Officer. Ms. Bemis is an accomplished biotech leader […] The post Vividion Therapeutics Announces Promotion of Jean Bemis to Chie...| Vividion Therapeutics
San Diego, CA, USA, Berlin, Germany and Durham, NC, USA January 8, 2025 Vividion Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing novel discovery technologies to unlock high-value, traditionally undruggable targets and develop small molecule precision therapeutics for devastating cancers and immune disorders, today announced the acquisition of Tavros Therapeutics, Inc., a precision oncology platform company. Vividion […] The post Vividion Therapeutics Acquires Tavro...| Vividion Therapeutics
San Diego, USA, October 8, 2024 – Vividion Therapeutics, Inc. (Vividion), a clinical stage biopharmaceutical company utilizing novel discovery technologies to unlock high-value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, today announced the appointment of Frank Poschen, a pioneer in organizational change and dynamic talent leader, to its Board of Directors […] The post Vividion Therapeutics Appoints Frank Poschen to Board o...| Vividion Therapeutics
San Diego, USA, July 23, 2024 – Vividion Therapeutics, Inc. (Vividion), a clinical stage biopharmaceutical company utilizing novel discovery technologies to unlock high-value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, today announced it will expand its global innovation capabilities with a new research and development (R&D) center and corporate headquarters […] The post Vividion Therapeutics to Expand with New Global Resear...| Vividion Therapeutics
SAN DIEGO – April 25, 2024– Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high-value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, today announced a landmark publication in Nature. The publication, “Chemoproteomic Discovery of a Covalent Allosteric Inhibitor of WRN Helicase,” by Kristen Baltgalvis et al, […] The post Vividion Therapeutics and Roche Jointly Publi...| Vividion Therapeutics
Due to the limits of traditional drug discovery, the vast majority of known disease-causing proteins remain undrugged. Our mission is to unlock these| Vividion Therapeutics
